United Therapeutics UTHR Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Adcirca | $2.9M-62.8% | $7.8M-19.6% | $9.7M+49.2% | $6.5M+8.3% | $6M+27.7% | |
| Nebulized Tyvaso | $127.2M+1.2% | $125.7M-11.4% | $141.8M-8.2% | $154.4M-5.7% | $163.8M+14.8% | |
| Orenitram | $135.6M+11.9% | $121.2M-7.6% | $131.1M+5.8% | $123.9M+2.7% | $120.7M+12.0% | |
| Remodulin | $126.6M-1.1% | $128M+1.7% | $125.9M-6.5% | $134.7M-2.5% | $138.2M+2.8% | |
| Tyvaso DPI | $330.3M-2.5% | $338.6M+0.7% | $336.2M+6.7% | $315.2M+4.2% | $302.5M+10.7% | |
| Unituxin | $53.6M-14.0% | $62.3M+30.1% | $47.9M-18.0% | $58.4M+0.3% | $58.2M-13.8% | |
| Gross Profit by Product | ||||||
| Adcirca | $1.9M-56.8% | $4.4M-17.0% | $5.3M+39.5% | $3.8M+11.8% | $3.4M+17.2% | |
| Nebulized Tyvaso | $118.6M-0.6% | $119.3M-11.7% | $135.1M-9.2% | $148.8M-4.2% | $155.3M+14.8% | |
| Orenitram | $128.2M+12.2% | $114.3M-8.0% | $124.3M+6.1% | $117.2M+4.3% | $112.4M+10.1% | |
| Remodulin | $110.5M-7.8% | $119.9M+6.3% | $112.8M-6.3% | $120.4M-3.2% | $124.4M+2.7% | |
| Tyvaso DPI | $247.1M-11.7% | $279.9M-0.4% | $280.9M+5.3% | $266.7M+4.8% | $254.4M+8.3% | |
| Unituxin | $48.6M-13.8% | $56.4M+27.3% | $44.3M-20.3% | $55.6M+4.9% | $53M-18.8% | |
| Cost of Sales by Product | ||||||
| Adcirca | $1M-70.6% | $3.4M-22.7% | $4.4M+63.0% | $2.7M+3.8% | $2.6M+44.4% | |
| Nebulized Tyvaso | $8.6M+34.4% | $6.4M-4.5% | $6.7M+19.6% | $5.6M-34.1% | $8.5M+14.9% | |
| Orenitram | $7.4M+7.2% | $6.9M+1.5% | $6.8M+1.5% | $6.7M-19.3% | $8.3M+45.6% | |
| Remodulin | $16.1M+98.8% | $8.1M-38.2% | $13.1M-8.4% | $14.3M+3.6% | $13.8M+3.0% | |
| Tyvaso DPI | $83.2M+41.7% | $58.7M+6.1% | $55.3M+14.0% | $48.5M+0.8% | $48.1M+25.3% | |
| Unituxin | $5M-15.3% | $5.9M+63.9% | $3.6M+28.6% | $2.8M-46.2% | $5.2M+136% | |
| Total revenues by Geography | ||||||
| ROW | $37.3M-0.3% | $37.4M+51.4% | $24.7M-36.3% | $38.8M-13.4% | $44.8M+48.3% | |
| U.S. | $744.2M-1.1% | $752.8M-2.8% | $774.8M+2.0% | $759.8M+1.4% | $749.6M+6.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
